StockData
Mangoceuticals, Inc. logo

Mangoceuticals, Inc. (MGRX) stock

MGRXNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$0.15−0.01 (-8.44%)

Close on Nov 18, 2026Market cap $3.16MP/E –Yield –

Mangoceuticals net income

Net income is the profit left for shareholders after every expense, interest and tax.

Mangoceuticals's net income for the twelve months ending Jun 30, 2026 was -$15.10M. For fiscal 2025 it was -$20.64M.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$20.64M–
FY2024Dec 31, 2024-$8.71M–
FY2023Dec 31, 2023-$9.21M–
FY2022Dec 31, 2022-$2.00M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$1.31M–
Q1 FY2026Mar 31, 2026-$3.40M–
Q4 FY2025Dec 31, 2025-$2.77M–
Q3 FY2025Sep 30, 2025-$7.62M–
Q2 FY2025Jun 30, 2025-$5.42M–
Q1 FY2025Mar 31, 2025-$4.84M–
Q4 FY2024Dec 31, 2024-$1.95M–
Q3 FY2024Sep 30, 2024-$2.00M–
Q2 FY2024Jun 30, 2024-$2.39M–
Q1 FY2024Mar 31, 2024-$2.37M–
Q4 FY2023Dec 31, 2023-$2.57M–
Q3 FY2023Sep 30, 2023-$1.80M–
Q2 FY2023Jun 30, 2023-$2.28M–
Q1 FY2023Mar 31, 2023-$2.56M–
Q4 FY2022Dec 31, 2022-$673.66K–
Q3 FY2022Sep 30, 2022-$994.92K–
Q2 FY2022Jun 30, 2022-$310.19K–
Q1 FY2022Mar 31, 2022-$19.60K–

More Mangoceuticals figures

See a number that looks wrong?